Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Desai J, et al. Among authors: prenen h. Nat Med. 2024 Jan;30(1):271-278. doi: 10.1038/s41591-023-02696-8. Epub 2023 Dec 5. Nat Med. 2024. PMID: 38052910 Free PMC article. Clinical Trial.
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Sacher A, et al. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. N Engl J Med. 2023. PMID: 37611121 Free article. Clinical Trial.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Clinical Trial.
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V. Prenen H, et al. Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677. Online ahead of print. Clin Cancer Res. 2024. PMID: 38709220
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition.
Deben C, Boullosa LF, Fortes FR, De La Hoz EC, Le Compte M, Seghers S, Peeters M, Vanlanduit S, Lin A, Dijkstra KK, Van Schil P, Hendriks JMH, Prenen H, Roeyen G, Lardon F, Smits E. Deben C, et al. Among authors: prenen h. J Exp Clin Cancer Res. 2024 Mar 22;43(1):88. doi: 10.1186/s13046-024-03012-z. J Exp Clin Cancer Res. 2024. PMID: 38515178 Free PMC article.
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer.
Le Compte M, De La Hoz EC, Peeters S, Fortes FR, Hermans C, Domen A, Smits E, Lardon F, Vandamme T, Lin A, Vanlanduit S, Roeyen G, Van Laere S, Prenen H, Peeters M, Deben C. Le Compte M, et al. Among authors: prenen h. NPJ Precis Oncol. 2023 Dec 8;7(1):128. doi: 10.1038/s41698-023-00480-y. NPJ Precis Oncol. 2023. PMID: 38066116 Free PMC article.
New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.
Janssens K, Lambrechts C, Geerinckx B, Op de Beeck K, Van Camp G, Oliveres H, Prenen H, Vandamme T, Peeters M. Janssens K, et al. Among authors: prenen h. Curr Treat Options Oncol. 2023 Aug;24(8):965-987. doi: 10.1007/s11864-023-01095-y. Epub 2023 May 22. Curr Treat Options Oncol. 2023. PMID: 37212934 Review.
167 results